Idaho Strategic Resources (IDR) is expected to report its third-quarter 2026 results in mid-November, with a consensus earnings per share (EPS) estimate of $0.30 and revenue of $14.10 million . The EPS estimate implies roughly 50% year-over-year growth , while the revenue estimate implies about 27% growth from the $11.08 million reported a year earlier.

PepGen reported a net loss of $19.4 million , or $0.28 per share , for the third quarter ended September 30, 2026. The per-share loss came in slightly wider than the consensus estimate of a $0.27 loss.

Prelude Therapeutics is expected to report third-quarter 2026 results before the market opens in mid-November, with a conference call to follow. Analyst estimates point to roughly breakeven earnings per share (EPS) and a sharp year-over-year revenue jump, driven largely by collaboration revenue recognition from the Incyte agreement.

Opus Genetics reported third-quarter 2026 revenue of $1.1 million, down from $3.1 million in the prior-year period and below analyst consensus expectations. Net loss widened to $46.5 million, or $0.46 per basic and diluted share, compared with a net loss of $17.5 million, or $0.25 per share, a year earlier.

Kyverna Therapeutics is a clinical-stage biotech with no commercial product revenue yet, so its third-quarter 2026 report will center on operating expenses and cash burn rather than sales. Wall Street consensus anticipates a net loss of roughly $0.69 per share for the third quarter of 2026, with essentially zero revenue expected.

United States Antimony Corporation (UAMY) is scheduled to report third quarter 2026 results for the three months ended September 30, 2026, after U.S. markets close on Thursday, November 12, 2026. Wall Street consensus, per TradingView, points to revenue of roughly $17.06 million and a net loss of $0.02 per share (EPS) for the quarter.

Revenue climbed 14.9% year over year to $146.3 million, narrowly topping the roughly $146.09 million consensus estimate and marking an eighth consecutive quarter of double-digit organic growth. Adjusted diluted earnings per share (EPS) of $0.09 missed the $0.10 consensus, while reported (IFRS) diluted EPS came in at $0.06.

DoubleDown Interactive reported third-quarter 2026 revenue of $94.3 million , down roughly 1.6% from $95.8 million a year earlier but slightly above consensus estimates. Net profit attributable to shareholders fell about 44% to $18.4 million, with basic and diluted earnings per share of $7.41 versus $13.21 in the prior-year period.

Integra Resources reported third-quarter 2026 revenue of $72.4 million, up slightly from $70.7 million a year earlier, while gold production at Florida Canyon fell to 17,652 ounces from 20,653 ounces. Net income swung to $12.9 million, or $0.06 per share, reversing a net loss of $8.2 million, or $0.05 per share, in Q3 2025, aided by a higher average realized gold price of $4,272 per ounce.

CorMedix (CRMD) is expected to report third-quarter 2026 results on November 11, 2026, before the market opens, with a conference call scheduled for November 12. Consensus estimates call for revenue of roughly $52.8 million and a net loss of approximately $0.09 per share , reflecting a sharp expected decline from the prior-year quarter's $104.3 million in revenue and $1.26 diluted EPS.

DiaMedica Therapeutics (NASDAQ: DMAC), a clinical-stage biopharmaceutical company, is expected to report third-quarter 2026 results in mid-November 2026. As a development-stage drugmaker with no marketed products, the company is expected to post zero revenue and a net loss per share of roughly -$0.21, in line with its recent run-rate.

Bally's reported preliminary third quarter 2026 consolidated revenue of $807.6 million, up 21.7% from $663.7 million a year earlier. Growth was led by Bally's Intralot business-to-consumer (B2C) revenue, up 22.8%, and North America Interactive, up 25.6%.

Ovid Therapeutics reported a third-quarter 2026 net loss of $20.8 million , or $0.10 per basic and diluted share , compared with a $12.2 million loss, or $0.17 per share, in the prior-year period. The reported loss per share came in below the consensus estimate of roughly -$0.08, largely reflecting a sharp increase in research and development (R&D) spending.

Afya Limited is scheduled to report its third-quarter 2026 results after the U.S. market close on Thursday, November 12, 2026, followed by a conference call at 5:00 p.m. ET. Wall Street consensus calls for earnings per share (EPS) near $0.37 and revenue of roughly $190 million, with individual analyst estimates ranging from $0.36 to $0.39 for EPS.

InMode reported third-quarter 2026 revenue of $92.1 million, roughly flat to down about 1% from $93.2 million a year earlier and in line with its pre-announced range of $91.8 million to $92.0 million. Non-GAAP (adjusted) diluted EPS came in at $0.37, topping the consensus estimate of roughly $0.32, while GAAP diluted EPS fell to $0.32 from $0.34 a year ago.

Third quarter 2026 net sales rose 4.6% year over year to $493 million, but landed below the roughly $520 million consensus estimate. Reported earnings per share (EPS) of $0.14 missed the $0.22 consensus, even as net income climbed to $10.8 million from $1.2 million a year earlier.

Alto Neuroscience (ANRO) reported a net loss of $25.1 million , or $0.54 per share , for the third quarter ended September 30, 2026, compared with a $14.2 million loss in the prior-year quarter. The reported loss per share was narrower than the roughly $0.67 per share loss Wall Street analysts had anticipated, according to consensus estimates.

Collective Mining (CNL) is expected to report its third-quarter 2026 results in mid-November 2026, covering the three months ended September 30, 2026. As a pre-revenue gold, silver, and copper explorer, CNL generates no meaningful sales, so the market focuses on its net loss per share and exploration spending.

Savara reported a third-quarter 2026 net loss of $42.99 million , up from $29.56 million in the same period a year earlier. Loss per share came in at $0.17 , versus $0.14 in Q3 2025 and slightly wider than the consensus estimate of roughly $0.16.

Riskified reported third quarter 2026 revenue of $115.2 million , up 41% year over year and above the roughly $103.4 million consensus estimate. Non-GAAP (adjusted) earnings per share came in at $0.07 , comfortably beating analyst expectations of about $0.03 to $0.04.